cAH Clinical Program - Spruce biosciences
Spruce Biosciences, a late-stage clinical development company focused on developing and commercializing novel therapies for rare endocrine disorders, has announced the launch of CAHstudy.com a new website and patient resource to enable adults with Congenital Adrenal Hyperplasia (CAH) to register their interest in the CAHmelia clinical program, which is expected to commence in the second half of 2020.
exciting news from nadf
April 25, 2020
We would like to take this opportunity to make some exciting and important announcements. We have seen rapid growth of our foundation over the past decade or so, with the trajectory of growth in the responsibilities required to run NADF accelerating equally as quickly.
We would like to take this opportunity to make some exciting and important announcements. We have seen rapid growth of our foundation over the past decade or so, with the trajectory of growth in the responsibilities required to run NADF accelerating equally as quickly.
COVID-19 DOSING RECOMMENDATIONS
For those with adrenal insufficiency and confirmed or suspected Covid-19, increase the dose of hydrocortisone to 20 mg every 6 hours until the fever subsides, and then go back to the usual double dose until completely better.
ADRENAL INSUFFICIENCY STUDY EXPANDS TO COVID MONITORING
This pandemic is frightening for everyone, but particularly for those who have chronic medical conditions. Adrenal insufficient patients have twin risks of possibly “catching” COVID-19 more easily and the additional problem of adrenal crisis complicating their ability to respond to a major illness.
April 9, 2020
As a follow-up to our March 13th bulletin, we are sharing an update regarding the availability of hydrocortisone tablets. The NADF team continues to support our community by working with the FDA and pharmaceuticals regarding the issues our adrenal insufficiency patients have been experiencing with their difficulty filling this life-preserving drug.
As a follow-up to our March 13th bulletin, we are sharing an update regarding the availability of hydrocortisone tablets. The NADF team continues to support our community by working with the FDA and pharmaceuticals regarding the issues our adrenal insufficiency patients have been experiencing with their difficulty filling this life-preserving drug.
